CervoMed
CRVO
CervoMed (CRVO) news
Recent news
Cervomed Q2 net income USD -6.6 million vs. IBES estimate USD -8.56 million
AInvest Wire · Aug 10, 2026Canaccord Genuity cuts target price to $18 from $27 for Cervomed Inc
Canaccord Genuity has revised its price target for CervoMed Inc. (NASDAQ: CRVO), lowering it to $18 from $27, while maintaining a Buy rating for the biopharmaceutical company. The adjustment reflects updated assumptions regarding the regulatory and commercial trajectory of CervoMed’s lead…
AInvest Wire · Aug 10, 2026Cervomed - files to register resale of 10.08 mln shares of common stock - SEC filing
AInvest Wire · Jul 6, 2026Cervomed announces closing of $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules
AInvest Wire · Jun 22, 2026Cervomed announces $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules
AInvest Wire · Jun 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.